Abstract

The mutation load in melanoma is generally high compared with other tumor types due to extensive UV damage. Translation of exome sequencing data into clinically relevant information is therefore challenging. This study sought to characterize mutations identified in primary cutaneous melanomas and correlate these with clinicopathologic features. DNA was extracted from 34 fresh-frozen primary cutaneous melanomas and matched peripheral blood. Tumor histopathology was reviewed by two dermatopathologists. Exome sequencing was conducted and mutation rates were correlated with age, sex, tumor site, and histopathologic variables. Differences in mutations between categories of solar elastosis, pigmentation, and BRAF/NRAS mutational status were investigated. The average mutation rate was 12 per megabase, similar to published results in metastases. The average mutation rate in severely sun damaged (SSD) skin was 21 per Mb compared with 3.8 per Mb in non-SSD skin (P=0.001). BRAF/NRAS wild-type (WT) tumors had a higher average mutation rate compared with BRAF/NRAS-mutant tumors (27 vs. 5.6 mutations per Mb; P=0.0001). Tandem CC>TT/GG>AA mutations comprised 70% of all dinucleotide substitutions and were more common in tumors arising in SSD skin (P=0.0008) and in BRAF/NRAS WT tumors (P=0.0007). Targetable and potentially targetable mutations in WT tumors, including NF1, KIT, and NOTCH1, were spread over various signaling pathways. Melanomas arising in SSD skin have higher mutation loads and contain a spectrum of molecular subtypes compared with BRAF- and NRAS-mutant tumors indicating multigene screening approaches and combination therapies may be required for management of these patients.

Highlights

  • The development of BRAF inhibitors, vemurafenib and dabrafenib, marked a turning point in the treatment and prognosis of patients with advanced stage metastatic melanoma

  • Tandem CC>TT/GG>AA mutations comprised 70% of all dinucleotide substitutions and were more common in tumors arising in severely sun damaged (SSD) skin (P 1⁄4 0.0008) and in BRAF/NRAS WT tumors (P 1⁄4 0.0007)

  • Melanomas were from the lower limb (47%), head and neck (26%), trunk (18%), and upper limb (9%)

Read more

Summary

Introduction

The development of BRAF inhibitors, vemurafenib and dabrafenib, marked a turning point in the treatment and prognosis of patients with advanced stage metastatic melanoma. The BRAF oncogene is mutated in up to 50% of cutaneous melanomas and its clinical and histologic associations have been well characterized [1, 2]. BRAF V600E mutations occur more commonly in patients under the age of 50 years with higher nevus counts, and are more common in melanomas arising on the trunk in intermittently sunexposed skin [1, 3]. They are more prevalent in superficial spreading melanomas (SSM) as compared with other melanoma subtypes and have characteristic histopathologic features [1, 4, 5].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call